Todd Verdoorn

Todd Verdoorn has extensive experience in the field of biopharmaceuticals and neuroscience. Todd currently serves as the Chief Scientist at Intuitive Quantitation, LLC, a company that provides strategic and tactical leadership for the development of new treatments for major diseases. In this role, Verdoorn focuses on delivering high-quality data, novel analysis, and clear communication to support critical decisions and advance successful development programs.

Prior to their current position, Verdoorn worked as a Research and Development Specialist at NeuroTrauma Sciences, LLC starting in 2020. Todd previously served as the Chief Scientific Officer at DiaMedica Inc. from 2016 to 2019, where they played a key role in the company's scientific operations.

Verdoorn's career also includes roles such as Vice President Neurobiology at NeuroTherapeutics Pharma, Inc., Chief Scientific Officer at Orasi Medical, Inc., and Chief Scientific Officer at SMART Bioscience. In these positions, they contributed significantly to the development of innovative technologies and treatments for diseases related to the central nervous system.

Earlier in their career, Verdoorn worked at Algos Preclinical Services, Inc., a biopharmaceutical start-up focused on chronic pain treatment strategies. Todd was a founding partner and served as the Chief Scientific Officer, raising initial venture funding and leading the scientific staff in drug discovery programs and contract research business development.

Before joining the private sector, Verdoorn worked as the Director of Neurology Drug Discovery at Bristol-Myers Squibb PRI. Todd provided strategic leadership and managed teams involved in neurology-focused drug discovery and development efforts, particularly in the areas of stroke and Alzheimer's disease.

Verdoorn began their career as a Postdoctoral Fellow at the Max Planck Institute for Medical Research and later became an Associate Professor at Vanderbilt University Medical Center. During this time, they established a well-funded laboratory, trained students and fellows, and published extensively in peer-reviewed journals.

Overall, Todd Verdoorn's work experience demonstrates their significant contributions to the field of biopharmaceuticals and neuroscience, particularly in the areas of drug discovery, scientific leadership, and strategic development.

Todd Verdoorn has a Ph.D. in Neurobiology from the University of North Carolina at Chapel Hill. Prior to that, they obtained a Bachelor of Arts degree in Chemistry from Central College. The specific start and end years for these educational experiences are not provided.